Pharmsynthez-Zerde is set to be constructed in Kazakhstan's Shymkent. The facility, which will produce drugs for the treatment of cardiovascular diseases, cancer, and HIV/AIDS, is a joint venture (JV) between Kazakhstan and Russian pharmaceutical company Pharmsynthez. The facility is anticipated to manufacture over 3 million packages a year, with the launch of the full production capacity expected in 2017.